PHVS
No price yet
Announcements
Nothing here yet
Daily updates
- Pharvaris published Phase 3 RAPIDe-3 results for on-demand deucrictibant immediate-release therapy in The Lancet, showing HAE attack symptom relief beginning at 1.28 hours and complete resolution by 11.95 hours, with a favorable safety profile.Oct 10, 2026
- Pharvaris' Phase 3 CHAPTER-3 trial met its primary endpoint for oral deucrictibant XR in HAE prophylaxisSep 8, 2026
- Deucrictibant data supported oral treatment of hereditary angioedemaSep 3, 2026
FDA designations
Nothing here yet
News
- Pharvaris reports publication in The Lancet of Phase 3 results demonstrating rapid and sustained efficacy of deucrictibant in treating HAE attacksOct 9, 2026
- Pharvaris' real-world analysis of hereditary angioedema disease experience and treatment satisfaction gaps is published in Advances in TherapyOct 5, 2026
- Pharvaris reported positive topline results from the pivotal Phase 3 CHAPTER-3 study of extended-release deucrictibant for HAE attack prophylaxisSep 8, 2026
- Study on AAE-C1INH disease burden and clinical trial endpoint validation was published in Frontiers in ImmunologyAug 6, 2026
- FDA accepted Pharvaris' new drug application for deucrictibant IR for on-demand treatment of hereditary angioedema attacksJul 8, 2026